Relapse: Surgical considerations and secondary cytoreduction

Sara M. Jordan, Robert E. Bristow

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter focuses on the survival bene fi t, selection criteria, and morbidity and mortality associated with secondary cytoreduction for recurrent ovarian cancer in the general population and the elderly. The goal of secondary cytoreduction is to improve overall survival by maximizing surgical tumor eradication in patients who demonstrate a complete clinical response to initial platinum-based chemotherapy. Retrospective studies consistently demonstrate a survival bene fi t associated with maximal secondary cytoreduction. Patient selection criteria should be individualized based on the patient's life goals, comorbidities and performance status, and availability of adjuvant therapy. Morbidity and mortality rates are comparable to those associated with primary cytoreduction. The role of secondary cytoreduction in the geriatric population is still evolving. In general, elderly are less likely to receive standard treatment for ovarian cancer, but research suggests that secondary cytoreduction can be both safe and feasible and advanced age alone should not be a contraindication to surgery.

Original languageEnglish (US)
Title of host publicationManagement of Gynecological Cancers in Older Women
PublisherSpringer-Verlag London Ltd
Pages183-198
Number of pages16
ISBN (Print)9781447146056, 9781447122159
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Patient Selection
Recurrence
Ovarian Neoplasms
Survival
Morbidity
Mortality
Platinum
Geriatrics
Population
Comorbidity
Retrospective Studies
Drug Therapy
Therapeutics
Research
Neoplasms

Keywords

  • Elderly
  • Recurrent epithelial ovarian cancer
  • Relapse
  • Secondary cytoreduction
  • Secondary cytoreductive surgery

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jordan, S. M., & Bristow, R. E. (2013). Relapse: Surgical considerations and secondary cytoreduction. In Management of Gynecological Cancers in Older Women (pp. 183-198). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-4605-6_12

Relapse : Surgical considerations and secondary cytoreduction. / Jordan, Sara M.; Bristow, Robert E.

Management of Gynecological Cancers in Older Women. Springer-Verlag London Ltd, 2013. p. 183-198.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jordan, SM & Bristow, RE 2013, Relapse: Surgical considerations and secondary cytoreduction. in Management of Gynecological Cancers in Older Women. Springer-Verlag London Ltd, pp. 183-198. https://doi.org/10.1007/978-1-4471-4605-6_12
Jordan SM, Bristow RE. Relapse: Surgical considerations and secondary cytoreduction. In Management of Gynecological Cancers in Older Women. Springer-Verlag London Ltd. 2013. p. 183-198 https://doi.org/10.1007/978-1-4471-4605-6_12
Jordan, Sara M. ; Bristow, Robert E. / Relapse : Surgical considerations and secondary cytoreduction. Management of Gynecological Cancers in Older Women. Springer-Verlag London Ltd, 2013. pp. 183-198
@inbook{46eb5c4a69174930af1b0a891497b161,
title = "Relapse: Surgical considerations and secondary cytoreduction",
abstract = "This chapter focuses on the survival bene fi t, selection criteria, and morbidity and mortality associated with secondary cytoreduction for recurrent ovarian cancer in the general population and the elderly. The goal of secondary cytoreduction is to improve overall survival by maximizing surgical tumor eradication in patients who demonstrate a complete clinical response to initial platinum-based chemotherapy. Retrospective studies consistently demonstrate a survival bene fi t associated with maximal secondary cytoreduction. Patient selection criteria should be individualized based on the patient's life goals, comorbidities and performance status, and availability of adjuvant therapy. Morbidity and mortality rates are comparable to those associated with primary cytoreduction. The role of secondary cytoreduction in the geriatric population is still evolving. In general, elderly are less likely to receive standard treatment for ovarian cancer, but research suggests that secondary cytoreduction can be both safe and feasible and advanced age alone should not be a contraindication to surgery.",
keywords = "Elderly, Recurrent epithelial ovarian cancer, Relapse, Secondary cytoreduction, Secondary cytoreductive surgery",
author = "Jordan, {Sara M.} and Bristow, {Robert E.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4471-4605-6_12",
language = "English (US)",
isbn = "9781447146056",
pages = "183--198",
booktitle = "Management of Gynecological Cancers in Older Women",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - Relapse

T2 - Surgical considerations and secondary cytoreduction

AU - Jordan, Sara M.

AU - Bristow, Robert E.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - This chapter focuses on the survival bene fi t, selection criteria, and morbidity and mortality associated with secondary cytoreduction for recurrent ovarian cancer in the general population and the elderly. The goal of secondary cytoreduction is to improve overall survival by maximizing surgical tumor eradication in patients who demonstrate a complete clinical response to initial platinum-based chemotherapy. Retrospective studies consistently demonstrate a survival bene fi t associated with maximal secondary cytoreduction. Patient selection criteria should be individualized based on the patient's life goals, comorbidities and performance status, and availability of adjuvant therapy. Morbidity and mortality rates are comparable to those associated with primary cytoreduction. The role of secondary cytoreduction in the geriatric population is still evolving. In general, elderly are less likely to receive standard treatment for ovarian cancer, but research suggests that secondary cytoreduction can be both safe and feasible and advanced age alone should not be a contraindication to surgery.

AB - This chapter focuses on the survival bene fi t, selection criteria, and morbidity and mortality associated with secondary cytoreduction for recurrent ovarian cancer in the general population and the elderly. The goal of secondary cytoreduction is to improve overall survival by maximizing surgical tumor eradication in patients who demonstrate a complete clinical response to initial platinum-based chemotherapy. Retrospective studies consistently demonstrate a survival bene fi t associated with maximal secondary cytoreduction. Patient selection criteria should be individualized based on the patient's life goals, comorbidities and performance status, and availability of adjuvant therapy. Morbidity and mortality rates are comparable to those associated with primary cytoreduction. The role of secondary cytoreduction in the geriatric population is still evolving. In general, elderly are less likely to receive standard treatment for ovarian cancer, but research suggests that secondary cytoreduction can be both safe and feasible and advanced age alone should not be a contraindication to surgery.

KW - Elderly

KW - Recurrent epithelial ovarian cancer

KW - Relapse

KW - Secondary cytoreduction

KW - Secondary cytoreductive surgery

UR - http://www.scopus.com/inward/record.url?scp=84904969379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904969379&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-4605-6_12

DO - 10.1007/978-1-4471-4605-6_12

M3 - Chapter

AN - SCOPUS:84904969379

SN - 9781447146056

SN - 9781447122159

SP - 183

EP - 198

BT - Management of Gynecological Cancers in Older Women

PB - Springer-Verlag London Ltd

ER -